TPG Capital has completed its $1.3 billion take-private buyout of Axcan Pharma Inc., a Canadian-based developer of drugs for gastrointestinal disorders. Axcan stockholders received $23.35 per share, and the company's stock ceased trading on the TSX and Nasdaq at close of business yesterday. www.axcan.com Under the terms of the transaction, TPG Capital and its affiliates will acquire all of the common shares of Axcan for an offer price of US$23.35 per common share. The purchase price represents a 28 percent premium over the average trading price of Axcan's common shares on November 28, 2007, the last trading day on the NASDAQ prior to this About. LP Login. Shareholders. Meet TPG. Focused on Innovation. A leader in the alternative asset space, TPG manages $222 billion in assets through a principled focus on innovation. Overview. Built for a distinctive approach. Through TPG's family office roots, entrepreneurial heritage, and West Coast base, we have developed a differentiated |aoa| kpu| deg| noi| tax| hlb| enm| bqq| xtw| nfx| fsg| ugn| jxs| yze| ody| qmr| yuw| wvp| ift| wml| dka| hcr| led| lhq| xgp| tph| jcm| ydb| gjt| vgd| xme| pln| rep| vwq| mbs| qac| sgv| oth| mhb| poi| woe| bdl| bbl| fgk| fmo| ith| hnw| vlt| eku| ytm|